Free public records show Xiamen Amoytop Biotech Co., Ltd. in 3 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Xiamen Amoytop Biotech Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
12 active studies led by Xiamen Amoytop Biotech Co., Ltd., of 32 in all
Source: ClinicalTrials.gov, Studies with Xiamen Amoytop Biotech Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Xiamen Amoytop Biotech Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Xiamen Amoytop Biotech Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Xiamen Amoytop Biotech Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Xiamen Amoytop Biotech Co., Ltd. is in.
Stories on the topics Xiamen Amoytop Biotech Co., Ltd. works in.
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
Read
COVID-19 testing created a huge, short-lived spike. Long-term demand for in-vitro diagnostics now comes from…
ReadSearch all reports for Xiamen Amoytop Biotech Co., Ltd. All companies